Authors

Latest:

Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced Melanoma

Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.

Alexander N. Shoushtari, MD

Latest:

Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma

Alexander N. Shoushtari, discusses the rationale for the phase 3 CheckMate-067 trial in advanced melanoma.

Alexander Perl, MD, Abramson Cancer Center, University of Pennsylvania

Alexander Perl, MD, Perelman School of Medicine, University of Pennsylvania

Alexander R. Menter, MD

Latest:

Dr. Menter on Neoadjuvant Immunotherapy in Early-Stage NSCLC

Alexander R. Menter, MD, oncologist, Kaiser Permanente, discusses the use of neoadjuvant immunotherapy in patients with early-stage non–small cell lung cancer (NSCLC).

Alexander Ring, MD

Latest:

Dr. Ring on Molecular Profiling of CTCs in Advanced Breast Cancer

Alexander Ring, MD, graduate student, University of Southern California, discusses a study investigating the molecular profiling of circulating tumor cells (CTCs) as a surrogate for distant metastasis in patients with stage IV breast cancer.

Alexander Spira, MD, PhD, FACP

Latest:

Dr Spira Details Future Directions for Amivantamab in NSCLC

Alexander I. Spira MD, PhD, FACP, FASCO, details the next steps for amivantamab in patients with EGFR–mutated locally advanced non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, Virginia Cancer Specialists, US Oncology

Latest:

Dr Spira on Updated MARIPOSA Trial Data in EGFR+ Advanced NSCLC

Alexander I. Spira MD, PhD, FACP, FASCO, discusses updated findings from the phase 3 MARIPOSA study in EGFR-mutated locally advanced or metastatic NSCLC.

Alexandra Drakaki, MD

Latest:

Dr Drakaki on Nivolumab/Ipilimumab in Advanced RCC With Sarcomatoid Differentiation

Alexandra Drakaki, MD, PhD, discusses nivolumab plus ipilimumab in the treatment of renal cell carcinoma with sarcomatoid differentiation.

Alexandra Taylor, MD

Latest:

Dr. Taylor on the Future of Treatments for Endometrial Cancer

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the future of treatments for patients with endometrial cancer.

Alexandra Thomas, MD

Latest:

Targeting Cell Cycle Progression: CDK4/6 Inhibition in Breast Cancer

Cyclin-dependent kinase (CDK) 4/6 inhibitors are novel agents that have shown promising results in the treatment of breast cancer.

Alexandria Phan, MD

Latest:

Dr. Phan Discusses Challenges With Treating pNETs

Alexandria Phan, MD, the director of GI Medical Oncology at Houston Methodist, discusses some of the challenges oncologists face with treating patients with pancreatic neuroendocrine tumors (pNETs).

Alexey V. Danilov, MD, PhD

Latest:

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Drs Danilov and O'Brien discuss updates with acalabrutinib, zanubrutinib, and pirtobrutinib in CLL that were presented at the 2024 ASH Annual Meeting.

Alexey V. Danilov, MD, PhD, Oregon Health & Science University

Alexey V Danilov, MD, PhD, University School of Medicine in Portland, Oregon

Alexis E. Horace, PharmD

Latest:

The Future of Melanoma Treatment

Drugs currently approved by the FDA for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. This article will explore pharmacologic agents currently being investigated for the treatment of melanoma.

Alfred L. Garfall, MD, Abramson Cancer Center

Latest:

CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Alfred L. Garfall, MD, MS

Latest:

Dr Garfall on Updated Safety Data for Teclistamab in R/R Myeloma

Alfred L. Garfall, MD, MS, discusses updated safety data for teclistamab in relapsed/refractory multiple myeloma.

Alfredo Addeo, MD

Latest:

Dr. Addeo Discusses the Need for Biomarkers in NSCLC

Alfredo Addeo, MD, consultant medical oncologist, University Hospital of Geneva, discusses the need for effective biomarkers in non–small cell lung cancer.

Ali McBride, PharmD, MS, BCOP

Latest:

Dr. McBride on Biosimilar Rituximab

Ali McBride, PharmD, MS, BCOP, discusses the oncology community’s reaction to biosimilars for rituximab (Rituxan).